INTRODUCTION:

Gelucires are a family of lipid-based excipients comprising glycerides and esters of polyethylene glycol (PEG), these two components conferring hydrophobic and hydrophilic properties to the vehicle. Each Gelucire is characterized by two numbers, the first referring to the nominal melting point of the base and the second to the HLB value. Gelucires come in a variety of grades with different melting points (from 33ºC to65ºC) and HLB values (from 1 to 14). Pharmaceutical applications of Gelucires are wide range of materials within the Gelucires group results in a wide range of properties, particularly in terms of melting/crystallization behavior and hydrophobicity.

Consequently, it is possible to choose the Gelucire according to the particular formulation requirement, either in terms of manufacturing method or the rate of drug release. Different rates of drug release can be obtained by mixing the same active substance with Gelucires of different melting points and HLB values^1,2,3,5.

Diabetes is one of the real reasons for death and handicap on the planet. The worldwide figure of individuals with diabetes is set to ascend from the present gauge of 150 million to 220 million in 2010 and 300 million in 2025. Most cases will be of sort II diabetes, because of stationary way of life and obesity¹.

Oral ingestion is the overwhelming and best course for medication conveyance due to their deliberate impacts, for example, tolerant acknowledgment, accommodation in organization, and savvy producing process. In the human body the living arrangement time of orally directed dose shape in the stomach is by and large short because of quick gastric discharging. Fast gastro intestinal travel could bring about fragmented medication discharge from the orally directed dose frame over the assimilation zone prompting to reduce efficacy². With a specific end goal to expand the bioavailability of such medications, the habitation time of the orally controlled dose shape in the upper GIT should be drawn out. The principle ways to deal with drawing out the gastric home time of pharmaceutical dose frames incorporate bioadhesive medication conveyance framework, which stick to mucosal surface; gadgets that quickly increase in size once they are in stomach to hinder the entry through the pylorus; and thickness control conveyance framework, which skim on gastric fluid^3-6.

As of late, much consideration has been centered around the utilization of fats and unsaturated fat as bearers in medication conveyance systems^7,8,9. The utilization of amphiphilic lipid glyceryl monooleate for the plan of drifting lattice system¹⁰. Gelucire is the group of vehicle got from blends of mono-, di-and tri-glycerides with PEG esters of unsaturated fats. These are accessible with scope of properties relying upon their HLB and softening point extend (33-65ºC). They have a wide assortment of use in pharmaceutical details. These are utilized as a part of the arrangement of quick discharge and maintained discharge definitions. Gelucire containing just PEG esters are by and large utilized as a part of the readiness of quick discharge plan. Inferable from their outrageous hydrophilicity and low thickness, Gelucire 50/13 might be viewed as a proper transporter for outlining quick discharge skimming drug conveyance system¹¹. Gelucire containing just glycerides or a blend of glycerides and PEG esters (Gelucire 39/01, 43/01) are utilized as a part of the readiness of maintained discharge definition. Attributable to their outrageous hydrophobicity and low thickness, Gelucire 39/01and 43/01 are considered as proper transporters for outlining maintained discharge skimming drug conveyance system^12,13,14.

Gastric floating drug delivery system (GFDDS) is especially valuable for medications that are basically caught up in the duodenum and upper jejunum portions¹⁵. The GFDDS can draw out the maintenance time of a dose frame in the stomach, consequently enhancing the oral bioavailability of the drug⁶. Delayed gastric maintenance enhances bioavailability, lessens tranquilize squander, and enhances solvency for medications that are less solvent in a high pH environment. It has applications likewise for neighborhood tranquilize conveyance to the stomach and proximal small digestive tract. Lipids are considered as other option to polymers in the outline of controlled medication conveyance frameworks because of their points of interest like (a) low liquefy thickness, in this manner deterring the need of natural solvents for solubilization, (b) the nonappearance of poisonous debasements, for example, remaining monomers impetus and initiators, and (c) the potential biocompatibility and biodegradability and avoidance of gastric bothering by shaping a coat around the drug⁷.

A plenty of antidiabetic medications are utilized, of which Glibenclamide and Metformin hydrochloride is a generally acknowledged mix of drugs¹⁶. The reason of Combinations of the Sulfonlyureas and the Biguanides is both are real oral antidiabetics. The sulfonylureas, for example, Glibenclamide act by empowering the discharge of insulin. Their objectives are insulin-delivering pancreatic β cells and the biguanides, for example, Metformin, repress glycogenesis and increment the fringe utilization of glucose. The biguanides must be dynamic within the sight of endogenous insulin. Since the presentation of the different antidiabetic medicaments, specialists endorse specifically oral medicines of diabetes which join these different items, that strengths patients to take these blends of medicaments a few times each day. Unavoidably, low consistence is then seen with respect to the patients, who are regularly elderly people. Under these conditions, oral medicines don't have the normal impacts and the patients endure genuine complexities. Therefore, consistence is a principal parameter for the viability of the treatment (counteractive action of genuine issue brought about by hyperglycemia and survival of the patient). By enhancing consistence, measurements mistakes and their harmful impacts would be restricted. Since sulfonylureas are fit for empowering insulin discharge, yet are not equipped for following up on insulin resistance, and biguanides can follow up on insulin resistance, while they are not ready to fortify insulin emission, the restorative method of reasoning propose the utilization of consolidated definitions of medicaments equipped for finding a solution for both the lack in insulin discharge and the insulin-resistance condition. At present 4 blends are advertised which utilize a mix of Metformin with Glibenclamide i.e Glucomide Lipha-Glibenclamide and Metformin (2.5 mg) (500 mg), Glibomet Guidotti-Glibenclamide and Metformin (2.5 mg) (400 mg), Suguan M Hoechst - Glibenclamide and Metformin (2.5 mg) (400 mg) and Bi-Euglucon M Boehringer M-Glibenclamide and Metformin (2.5 mg) (400 mg)¹⁷.

The capacity of lipid-based plans to encourage gastrointestinal ingestion of numerous inadequately solvent medication applicants has been altogether reported in the distributed writing. In any case, an extensive hole exists between our insight into this innovation and the know-how required for its application. This discourse gives a far reaching synopsis of the advancement, portrayal, and use of oral lipid-based definitions, from both physicochemical and biopharmaceutical points of view. The qualities of right now accessible lipid excipients are checked on in setting of their application to the fundamental lipid-based plan modalities⁷. Advancement of new medication substances is posturing genuine test to formulators, especially because of their poor watery solvency which thus is likewise a main consideration in charge of their poor oral bioavailability. Lipids as transporters, in their different structures, have the capability of giving unlimited open doors in the range of medication conveyance because of their capacity to improve gastrointestinal solubilization and assimilation by means of particular lymphatic take-up of ineffectively bioavailable medications. These properties can be gathered to enhance the remedial viability of the medications with low bioavailability, and also to diminish their viable measurements requirement⁹.

Glibenclamide, an oral hypoglycemic of the sulphonyl urea gathering and Metformin hydrochloride, antidiabetic operator of biguanide gathering, are utilized as a part of the administration of sort 2 diabetes mellitus (non insulin subordinate, NIDDM). Glibenclamide works by repressing ATP-delicate potassium directs in pancreatic beta cells and expanding the arrival of insulin upto serum glucose level by setting off an expansion in intracellular calcium into the β cells of pancreas. Metformin acts by diminishing hepatic glucose generation, intestinal ingestion of glucose and enhances insulin affectability.

Glibenclamide is a low dosage, ineffectively solvent medication with conceivable substance consistency issues and disintegration rate-restricted bioavailability. The helpful measurement of Glibenclamide is 5-15 mg day by day, with low bioavailability and half life around 10 hrs. In any case, bioavailability of medication has been found to lessen facilitate with ordinary dose shape likely because of the way that section of the single unit measurements type of the medication is speedier than its discharge and a large portion of the medication discharges at the colon. Accordingly, it is alluring to enhance the prior reviews by defining quick discharge gastro retentive multi-particulates framework. Solvency upgrade for glibenclamide (inadequately watery solvent medication) is an imperative part of definition advancement. Despite the fact that there is a plenty of reports of dissolvability change utilizing distinctive strategies, a relative investigation of various solubilization methodologies are few¹⁹. Along these lines, the review created an imperative dataset in order to think about impact of different solubilizers on dissolvability of Glibenclamide. Fluid dissolvability of any restoratively dynamic substance is a key property as it oversees disintegration, retention and subsequently the adequacy in vivo. Solubilization might be characterized as the planning of a thermodynamically stable arrangement of a substance that is typically insoluble or somewhat dissolvable in a given dissolvable, by the presentation of at least one amphiphilic component(s). Solubilization of inadequately fluid dissolvable medication shapes an imperative action in definition process²⁰. Dissolvability profile with water-cosolvent frameworks, for example, PEG-400 and PEG-600 indicated exponential increment in solvency with increment in cosolvent part. The addition in dissolvability was observed to be 80-overlay and 59-crease for PEG 400 and PEG 600 at 25% cosolvent level²¹. As of late, surfactants have been incorporated to settle the plans, in this way staying away from medication recrystallization and potentiating their dissolvability. New assembling procedures to acquire strong scatterings have additionally been produced to lessen the downsides of the underlying procedure. In this survey, it is expected to examine the late advances related on the territory of strong dispersions²²

Strong scattering strategy was chosen as it was used in a set number of investigates to build the dissolvability of Glibenclamide. Strong scatterings are a standout amongst the most encouraging systems to enhance the oral bioavailability of inadequately water solvent medications. By lessening drug molecule size to indisputably the base, and thus enhancing drug wettability, bioavailability might be essentially made strides. Strong scattering is characterized as the scattering of at least one dynamic fixings in latent transporters at strong state arranged by combination, dissolvable or dissolvable combination strategies. It has been generally used to enhance the disintegration rate, dissolvability and oral retention of inadequately water-solvent medications. PEG and Gelucire are among the few transporters which have been utilized in planning strong scatterings. PEG polymers are broadly utilized for their low dissolving point, low lethality and wide medication similarity. Consequently, the review produced a vital dataset in order to look at impact of different solubilizers on solvency of glibenclamide. Strong scatterings of glibenclamide (inadequately water-dissolvable medication) and polyglycolized glycerides (Gelucire®) with the guide of silicon dioxide (Aerosil® 200); as an adsorbent, were set up by shower drying strategy. Strong scatterings and splash dried glibenclamide in correlation with immaculate glibenclamide and relating physical blends were at first portrayed and after that subjected to maturing study up to 3 months. Starting portrayal of Solid scatterings and shower dried glibenclamide by DSC and XRPD demonstrated that glibenclamide was available in its undefined frame (AGBM)²³. Glibenclamide is a moment era orally managed sulphonylurea subsidiary with intense hypoglycemic activity²⁴. Utilization of low liquefying point excipients like polyethylene glycols (PEG) and polyglycolized glycerides have been utilized broadly as excipients in strong scatterings. These excipients have appeared to bring about speedier medication disintegration by enhancing wettability of the medication particles, noteworthy lessening in molecule estimate amid the development of strong scatterings or the innately higher rate of disintegration of the dissolvable segment of strong scatterings, which would pull along the more insoluble however finely blended medication into the disintegration medium^25,26,27.

The polyglycolized glycol esters like Gelucires® are accounted for to lessen whimsical bioavailability of inadequately water dissolvable drugs²⁸. The utilization of nimodipine– polyethylene glycol strong scatterings, for the advancement of fizzing controlled discharge gliding tablet plans. The physical condition of the scattered nimodipine in the polymer framework was portrayed by differential examining calorimetry, powder X-beam diffraction, FT-IR spectroscopy and energized light microscopy²⁹.

The reason for the present review survey could be used to inspect the strong state properties of the strong scattering arrangement of Glibenclamide utilizing different evaluations of PEGs and Gelucire 50/13 arranged at various proportions. The strategies for portrayal can be accomplished through utilizing diverse apparatuses as FTIR, Differential checking calorimetry, Powder X-beam diffractometry. Also, dissolvability and disintegration rate study to be performed to qualify the strong scatterings contrasting and the medication alone or as physical blends.

Then again, Metformin hydrochloride is an oral antidiabetic medicate. Proceeded with endeavors to create metformin oral measurement frame for accomplishing an ideal treatment is required. These endeavors for the most part concentrate on controlled/moderate arrival of the medication including the complex gastroretentive framework^{5, 30}. Metformin is an antidiabetic specialist of biguanide gathering and utilized as a part of the administration of sort II diabetes mellitus (non insulin subordinate, NIDDM). Metformin acts by diminishing hepatic glucose creation, intestinal retention of glucose and enhances insulin affectability. Metformin has end half-existence of 6.5 h. Despite its positive clinical reaction and absence of huge downsides, constant treatment with metformin experiences certain particular issues of which the most noticeable are the high measurement (1.5–2.0 g/day), low bioavailability (60%), and high occurrence of gastrointestinal (GI) symptoms (30% cases). There have been opposing reports on the usage of metformin hydrochloride in single unit gastroretentive dose form³¹. In any case, bioavailability of this medication has been found to lessen encourage with control discharge measurement frame presumably because of the way that section of the control discharge single unit dose type of the medication is quicker than its discharge and the vast majority of the medication discharges at the colon, where metformin is inadequately absorbed^32,
33.Hence, it is attractive according to current audit to enhance bioavailability by detailing metformin hydrochloride in managed discharge gastro retentive multiparticulate framework utilizing Gelucires so as to streamline the pharmacokinetics and pharmacodynamics of the drug^{34, 35, 36}. Metformin HCl ranges from 0.5-2.5 gm every day isolated in a few measurements brought with dinners. The low bioavailability (50-60%) and short plasma half - life (1.7–4.5 hrs) of metformin hydrochloride make the improvement of managed discharge shapes desirable³⁷. In any case, medicate ingestion is constrained to the upper gastrointestinal (GI) tract, in this manner requiring reasonable conveyance frameworks giving complete discharge amid stomach-to-jejunum travel. Metformin hydrochloride is an exceedingly water-dissolvable hostile to hyperglycaemic operator utilized as a part of the treatment of sort II non-insulin-subordinate diabetes mellitus^{38, 39}. Gastric- retentive swelling tablets of metformin indicated just a 15% expansion of bioavailability as for the prompt discharge tablets⁴⁰.

CONCLUSION:

The present short survey propose the likelihood of Gelucire application to accomplish detailing of gastro retentive strong scattering of inadequately solvent medication Glibenclamide with the assistance of polyethylene glycol and Gelucire 50/13. Then again supported discharge gastroretentive multiparticulates of metformin hydrochloride could be accomplished utilizing Gelucire 39/01 and 43/01 grades. Facilitate both plans can be investigated individual and also in mix for enhanced bioavailability by their pharmacokinetic and pharmacodynamic assessment in wistar rats.

REFERENCES:

1. Kim K H and Singh B N, Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention, J Contr Rel, 63 (2000) 235-259.

2. Prashant Upadhyay, Jayanta Kumar Pandit and Arun Kumar Wahi, Gelucire: An alternative formulation technological tool for both sustained and fast release of drugs in treating diabetes mellitus type II disease, Journal of Scientific and Industrial Research72 (2013) 776-780

3. Lee J W, Park J H and Robinson J P, Bioadhesive based dosage forms, the next generation, J Pharm Sci, 89 (2000) 850-866.

4. King H, Aubert R E and Herman W H, Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections, Diabetes Care, 21 (1998) 1414–1431.

5. Fukuda M, Peppas N A and Mcginity J W, Floating hot melt extruded tablets for gastroretentive controlled drug release system, J Contr Rel, 115 (2006) 121-129.

6. Bardonnet P L, Faiere V and Jpugh W, Gastroretentive dosage forms: overview and special case of helicobacter pylori, J Contr Rel, 111 (2006) 1-18.

7. Hauss D J, Oral lipid-based formulations, Adv Drug Deliv Rev, 59 (2007) 667–676.

8. Streubel A, Siepmann J and Bodmeier R, Gastroretentive drug delivery system, Expert Opin, Drug Deliv, 3 (2006) 217-233.

9. Singh S, Chakraborty S, Shukla D and Mishra B, Lipid - An emerging platform for oral delivery of drugs with poor bioavailability, Eur J Pharm Biopharm, 73 (2009) 1–15.

10. Jannin V, Musakhanian J and Marchaud D, Approaches for the development of solid and semi-solid lipid-based formulations, Adv Drug Deliv Rev, 60 (2008) 734–746.

11. Paradkar A, Shah M H, Ketkar A and Mahadik K R, Effect of drug solubility and different excipients on floating behaviour and release from glyceryl monooleate matrices, Int J Pharm, 272 (2004) 151-160.

12. Fini A, Moyano J R, Gine´s J M, Perez-Martinez J I and Rabasco A M, Diclofenac salts II Solid dispersions in PEG 6000 and Gelucire 50/13, Eur J Pharm Biopharm, 60 (2005) 99–111.

13. Paradkar A, Shimpi S, Chauhan B and Mahadik K R, Preparation and evaluation of Diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by melt granulation,AAPS PharmSciTech, 5 (2004) 1-6.

14. Paradkar A, Mahadik K R, Chauhan B and Shimpi S, Preparation and evaluation of floating risedronate sodium Gelucire 39/01 matrices, Acta pharm, 54 (2004) 205-214.

15. Ali J, Arora S, Ahuja A, Babbar A K, Sharma R K, Khar R K and Baboota S, Formulation and development of hydrodynamically balanced system for metformin: In vitro and in vivo evaluation, Eur J Pharm Biopharm, 67 (2007) 196–201.

16. Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E, Gori M, Coppini A and Moghetti P, Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study, Metabolism, 52 (2003) 862 – 867.

17. Arora S, Ali J, Ahuja A, Khar R K and Baboota S, Floating Drug Delivery Systems: A Review, AAPS PharmSciTech, 6 (2005) E372-E390.

18. Snigdha P, Harikrishnan V, Jidesh K M et al. Formulation and Evaluation of Effervescent Floating Matrix Tablets of Venlafaxine Hydrochloride using Semi Synthetic Polymers. Inventi Rapid: NDDS, 2017(1):1-6, 2016.

19. Upadhyay P, Upadhyay S, Ghosh A K and Pandit J K, Studies on Formulation and optimization of Gastro Retentive multi-Particulates of Glibenclamide and Metformin hydrochloride for the treatment of Type II Diabetes mellitus using Gelucire: A Review, J Pharm Sci and Res, 2 (2010) 351-354.

20. Kawakami K, Oda N, Miyoshi K, Funaki T and Ida Y, Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents, Eur J Pharm Sci, 28 (2008) 7–14.

21. Porter C J H, Pouton C W, Cuine J F and Charman W N, Enhancing intestinal drug solubilisation using lipid-based delivery systems, Adv Drug Deliv Rev, 60 (2008) 673–691.

22. Urbanetz N A and Lippold B C, Solid dispersions of nimodipine and polyethylene glycol 2000: dissolution properties and physico-chemical characterization, Eur J Pharm Biopharm, 59 (2005) 107–118.

23. Unger J, Tajarobi F, Norder O, Frenning G and Larsson A, Relating solubility data of parabens in liquid PEG 400 to the behaviour of PEG 4000-parabens solid dispersions, Eur J Pharm Biopharm, 73 (2009) 260–268.

24. Vasconcelos T, Sarmento B and Costa P, Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs, Drug Discovery Today, 12 (2007) 1068-1075.

25. Paradkar A, Shimpi S and Chauhan B, Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique, Eur J Pharm Sci, 26 (2005) 219–230.

26. Davis S N and Granner D K, Insulin, oral hypoglycemic agents and the pharmacology of endocrine pancreas, In: Gilman, AG (Ed), The Pharmacological Basis of Therapeutics, ninth ed, McGraw-Hill, New York, (1996) 1487–1518.

27. Dordunoo S K, Ford J L, and Rubinstein M H, Preformulation studies on solid dispersions containing triamterene or temazepam in polyethylene glycols or Gelucire 44/14 for liquid filling of hard gelatin capsules, Drug Dev Ind Pharm, 17 (1991) 1685–1713.

28. Harikrishnan V, Jayeshv V N, Akashmarathakam, Sreejith M. Formulation, In-vitro Evaluation of Sustained Release Matrix Tablets of Lornoxicam using Okra Gum as Release Modifier. Inventi Rapid: NDDS, 2013(2): 1-4, 2013.

29. Leuner C and Dressman J, Improving drug solubility for oral delivery using solid dispersions, Eur J Pharm Biopharm, 50 (2000) 47–60.

30. Passerini N, Perissutti B, Moneghini M, Voinovich D, Albertini B, Cavallari C and Rodriguez L, Characterization of carmazepine gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasound, J Pharm Sci, 91 (2002) 699–707.

31. Pozzi F, Longo A, Lazzarini C and Carenzi A, Formulations of Ubidecarenone with improved bioavalibility, Eur J Pharm Biopharm, 37 (1991) 243–246.

32. Kachrimanis K, Solid dispersions in the development of a nimodipine floating tablet formulation and optimization by artificial neural networks and genetic programming. Eur J Pharm Biopharm, 77 (2011) 122–131.

33. Basak S C, Kumar K S and Ramalingam M, Design and release characteristics of sustained release tablet containing metformin HCl, Braz J Pharm Sci, 44 (2008) 477-483.

34. Hoffman A, Stepensky D, Lavy E, Eyal S, Klausner E and Friedman M, Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage form, Int J Pharm, 277 (2004) 141-153.

35. Vidon N, Chanssade S and Noel M, Metformin in digestive tract, Diabetes res clin pract, 4 (1998) 223-229.

36. Mavathe P H, Wen Y and Norton I, Effect of altered gastric emptying and gastrointestinal mobility on bioavailability of Metformin, AAPS annual meeting, New Orleans, 3 (1999) 567.

37. Verhoeven E, De Beer T R M, Schacht E, Mooter G V, Remon J P and Vervaet C, Influence of polyethylene glycol/polyethylene oxide on the release characteristics of sustained-release ethylcellulose mini-matrices produced by hot-melt extrusion: in vitro and in vivo evaluations, Eur J Pharm Biopharm, 72 (2009) 463–470.

38. Mura P, Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-b-cyclodextrin, Eur J Pharm Biopharm, 68 (2008) 303–309.

39. Pentikainen P J, Neuvonen P J and Penttila A, Pharmacokinetics of metformin after intravenous and oral administration to man, Eur J Clin Pharmacol, 16 (1979) 195–202.

40. usler G, Gorsline J, Levy G, Zhang S Z, Weston I E, Naret D and Berner B, Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers, J Clin Pharmacol, 41 (2001) 655–661.

Received on 20.01.2017 Accepted on 12.02.2017

Asian J. Res. Pharm. Sci. 2017; 7(1): 33-37.

DOI: 10.5958/2231-5659.2017.00006.6

ABSTRACT: